Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Alpha-1 MP in Alpha-1-antitrypsin Deficiency
NCT00301366Phase 3Completed
- Sponsor
- Grifols
- Start
- Jun 2006
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Started Jun 2006; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00301366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301366.